Michael E. Coats

TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.

TL;DR: NAB directed against IFN-β have in vivo biological consequences in patients with MS and treatment decisions in MS patients treated withIFN- β should take into account development of NAB.

TL;DR: Once weekly intramuscular IFNβ‐1a appears to impede the development of multiple sclerosis lesions at an early stage and has a favorable impact on the long‐term sequelae of these inflammatory events as indicated by the slowed accumulation of T2 lesions.

TL;DR: It is demonstrated that IFNβ-1a treatment is associated with robust, clinically important beneficial effects on disability progression in relapsing MS patients and post hoc analyses related to disability outcomes using data collected during the double-blind, placebo-controlled phase III clinical trial.

TL;DR: In this paper, simple and choice reactions times (RT) were slow at initial evaluation and became progressively slower at 6-month re-evaluation (P less than 0.05).